{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:10Z","timestamp":1772164810125,"version":"3.50.1"},"reference-count":69,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In the United States, Endometrial carcinoma (EC) is the most frequently occurring gynecologic cancer. Many ECs harbor mutations in cell cycle regulatory genes including TP53 and RB1, amongst others. RB and p53 both regulate the G1\/S transition while p53 also regulates the G2\/M transition and mitotic progression, all of which rely on targetable regulatory kinases. It is likely that many ECs harbor targetable defects in some aspect of cell cycle regulation, but there has been no profiling of p53- or RB- linked cell cycle functional capacity and corresponding therapeutic vulnerabilities in EC cells. Here, we utilize functional and transcriptomic assays on a panel of EC cell lines and patient-derived organoids to characterize the p53 and RB cell cycle regulatory proficiency and linked therapeutic vulnerabilities in EC. We show that TP53 genomic and functional status has poor predictive capacity for EC therapeutic response. Rather, proper RB regulation correlates with response to G1\/S targeting CDK4\/6 inhibitors, and dysfunction in regulation of mitotic progression correlates with response to Aurora kinase B inhibitors. A subset of TP53 mutant ECs are RB1 wild type, express RB protein, have intact RB regulation, and are sensitive to CDK4\/6 inhibitors, suggesting that excluding patients from emerging CDK4\/6 inhibitor trials based on aggressive histology or TP53 status should be reconsidered. These findings were validated in vivo in xenograft models. These results can expand current EC molecular stratification to include mechanism-driven subtypes and suggest clinical trials of novel targeted therapies based on biologic understanding for advanced or recurrent EC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We show novel cell cycle regulatory molecular classifications and therapeutic targets for endometrial carcinoma. Intact RB regulation and mitotic progression regulatory defects correlate with CDK4\/6 and Aurora kinase B inhibitor sensitivity respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0028","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:57:47Z","timestamp":1739264267000},"page":"719-742","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-1451","authenticated-orcid":false,"given":"Zelei","family":"Yang","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9944-3335","authenticated-orcid":false,"given":"Saie","family":"Mogre","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-7103","authenticated-orcid":false,"given":"Hyeji","family":"Jun","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8215-8439","authenticated-orcid":false,"given":"Ruiyang","family":"He","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4031-9152","authenticated-orcid":false,"given":"Sneha","family":"Ghosh Chaudhary","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-7218","authenticated-orcid":false,"given":"Upendra Raj","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"3Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-4709","authenticated-orcid":false,"given":"Shannan J.","family":"Ho Sui","sequence":"additional","affiliation":[{"name":"3Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-6992","authenticated-orcid":false,"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"4Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-9588","authenticated-orcid":false,"given":"Suzan","family":"Lazo","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-9589","authenticated-orcid":false,"given":"Aniket","family":"Shetty","sequence":"additional","affiliation":[{"name":"5Center for Patient-Derived Models, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9609-8134","authenticated-orcid":false,"given":"Amy","family":"Cameron","sequence":"additional","affiliation":[{"name":"6Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9043-4413","authenticated-orcid":false,"given":"Quang-D\u00e9","family":"Nguyen","sequence":"additional","affiliation":[{"name":"6Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-9459","authenticated-orcid":false,"given":"Sarah J.","family":"Hill","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"4Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2025051309090612300_bib1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"key":"2025051309090612300_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2025051309090612300_bib3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1136\/ijgc-2023-004939","article-title":"PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial","volume":"33","author":"Loukovaara","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025051309090612300_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2023.09.009","article-title":"TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes","volume":"178","author":"Whelan","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025051309090612300_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/GCO.0000000000000855","article-title":"Treatment options for molecular subtypes of endometrial cancer in 2023","volume":"35","author":"Karpel","year":"2023","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2025051309090612300_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/ijgc-2022-003676","article-title":"Biomarker-driven therapy in endometrial cancer","volume":"33","author":"Karpel","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"2025051309090612300_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"2025051309090612300_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"2025051309090612300_bib9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"key":"2025051309090612300_bib10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","article-title":"Regulation of the G2\/M transition by p53","volume":"20","author":"Taylor","year":"2001","journal-title":"Oncogene"},{"key":"2025051309090612300_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"2025051309090612300_bib12","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/s41418-023-01196-z","article-title":"Cyclers\u2019 kinases in cell division: from molecules to cancer therapy","volume":"30","author":"Milletti","year":"2023","journal-title":"Cell Death Differ"},{"key":"2025051309090612300_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrc2964","article-title":"Shared and separate functions of polo-like kinases and aurora kinases in cancer","volume":"10","author":"Lens","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2025051309090612300_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"key":"2025051309090612300_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2025051309090612300_bib16","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO\/ENGOT-EN3 trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"2025051309090612300_bib17","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.gore.2024.101348","article-title":"Combined aromatase, CDK4\/6 and PI3K blockade using letrozole\/abemaciclib\/LY3023414 in endometrial cancer","volume":"52","author":"Konstantinopoulos","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"2025051309090612300_bib18","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2024.42.16_suppl.5511","article-title":"A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer","volume":"42","author":"Green","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025051309090612300_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2015.00285","article-title":"A cell biologist\u2019s field guide to aurora kinase inhibitors","volume":"5","author":"de Groot","year":"2015","journal-title":"Front Oncol"},{"key":"2025051309090612300_bib20","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/onc.2013.325","article-title":"p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases","volume":"33","author":"Marxer","year":"2014","journal-title":"Oncogene"},{"key":"2025051309090612300_bib21","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.18632\/oncotarget.2190","article-title":"The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy","volume":"5","author":"Asteriti","year":"2014","journal-title":"Oncotarget"},{"key":"2025051309090612300_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","article-title":"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"127","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2025051309090612300_bib23","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1158\/1078-0432.CCR-12-0571","article-title":"Phase I pharmacokinetic\/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"Cervantes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025051309090612300_bib24","doi-asserted-by":"crossref","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025051309090612300_bib25","doi-asserted-by":"crossref","first-page":"e000718","DOI":"10.1136\/esmoopen-2020-000718","article-title":"Aurora kinases in ovarian cancer","volume":"5","author":"P\u00e9rez-Fidalgo","year":"2020","journal-title":"ESMO Open"},{"key":"2025051309090612300_bib26","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.3390\/molecules28083385","article-title":"Aurora B inhibitors as cancer therapeutics","volume":"28","author":"Kovacs","year":"2023","journal-title":"Molecules"},{"key":"2025051309090612300_bib27","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41416-023-02185-2","article-title":"Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours","volume":"128","author":"Johnson","year":"2023","journal-title":"Br J Cancer"},{"key":"2025051309090612300_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.seminoncol.2015.09.022","article-title":"Aurora kinase inhibitors in oncology clinical trials: current state of the progress","volume":"42","author":"Falchook","year":"2015","journal-title":"Semin Oncol"},{"key":"2025051309090612300_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2015.00278","article-title":"Aurora kinase inhibitors: current status and outlook","volume":"5","author":"Bavetsias","year":"2015","journal-title":"Front Oncol"},{"key":"2025051309090612300_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Aurora kinases as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2025051309090612300_bib31","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 inhibitors in cancer therapy: from laboratory to clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2025051309090612300_bib32","doi-asserted-by":"crossref","first-page":"903016","DOI":"10.3389\/fonc.2022.903016","article-title":"Present and future perspective on PLK1 inhibition in cancer treatment","volume":"12","author":"Chiappa","year":"2022","journal-title":"Front Oncol"},{"key":"2025051309090612300_bib33","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051309090612300_bib34","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1038\/s41388-021-01925-z","article-title":"PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer","volume":"40","author":"Fares","year":"2021","journal-title":"Oncogene"},{"key":"2025051309090612300_bib35","doi-asserted-by":"crossref","first-page":"zcae003","DOI":"10.1093\/narcan\/zcae003","article-title":"The ORFIUS complex regulates ORC2 localization at replication origins","volume":"6","author":"Yang","year":"2024","journal-title":"NAR Cancer"},{"key":"2025051309090612300_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","article-title":"In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma","volume":"102","author":"El-Sahwi","year":"2010","journal-title":"Br J Cancer"},{"key":"2025051309090612300_bib37","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3390\/ijms19082348","article-title":"Modeling endometrial cancer: past, present, and future","volume":"19","author":"Van Nyen","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025051309090612300_bib38","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1111\/jcmm.16397","article-title":"Gynaecological cancers and their cell lines","volume":"25","author":"Skok","year":"2021","journal-title":"J Cell Mol Med"},{"key":"2025051309090612300_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2025051309090612300_bib40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3892\/ijo.2020.5139","article-title":"Genomic characterization of five commonly used endometrial cancer cell lines","volume":"57","author":"Devor","year":"2020","journal-title":"Int J Oncol"},{"key":"2025051309090612300_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0090-8258(84)90080-5","article-title":"KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer","volume":"17","author":"Richardson","year":"1984","journal-title":"Gynecol Oncol"},{"key":"2025051309090612300_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10616-017-0149-5","article-title":"A guide for endometrial cancer cell lines functional assays using the measurements of electronic impedance","volume":"70","author":"Kozak","year":"2018","journal-title":"Cytotechnology"},{"key":"2025051309090612300_bib43","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/138161211795222603","article-title":"Pharmacologic activation of p53 by small-molecule MDM2 antagonists","volume":"17","author":"Shen","year":"2011","journal-title":"Curr Pharm Des"},{"key":"2025051309090612300_bib44","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"2025051309090612300_bib45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cell.2024.02.043","article-title":"p53: a tale of complexity and context","volume":"187","author":"Oren","year":"2024","journal-title":"Cell"},{"key":"2025051309090612300_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.gendis.2022.11.022","article-title":"Ribonucleotide reductase M2 (RRM2): regulation, function and targeting strategy in human cancer","volume":"11","author":"Zuo","year":"2024","journal-title":"Genes Dis"},{"key":"2025051309090612300_bib47","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Torres-Guzm\u00e1n","year":"2017","journal-title":"Oncotarget"},{"key":"2025051309090612300_bib48","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/j.1460-2075.1995.tb07276.x","article-title":"A pre-start checkpoint preventing mitosis in fission yeast acts independently of p34cdc2 tyrosine phosphorylation","volume":"14","author":"Hayles","year":"1995","journal-title":"EMBO J"},{"key":"2025051309090612300_bib49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-022-04698-x","article-title":"CDC7-independent G1\/S transition revealed by targeted protein degradation","volume":"605","author":"Suski","year":"2022","journal-title":"Nature"},{"key":"2025051309090612300_bib50","doi-asserted-by":"crossref","first-page":"100394","DOI":"10.1016\/j.xcrm.2021.100394","article-title":"CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models","volume":"2","author":"Xu","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025051309090612300_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.198","article-title":"Dual CCNE1\/PIK3CA targeting is synergistic in CCNE1-amplified\/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo","volume":"115","author":"Cocco","year":"2016","journal-title":"Br J Cancer"},{"key":"2025051309090612300_bib52","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/0008-5472.CAN-18-1235","article-title":"Low-molecular-weight cyclin E in human cancer: cellular consequences and opportunities for targeted therapies","volume":"78","author":"Caruso","year":"2018","journal-title":"Cancer Res"},{"key":"2025051309090612300_bib53","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1128\/MCB.21.18.6254-6269.2001","article-title":"Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms","volume":"21","author":"Porter","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2025051309090612300_bib54","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-06-2979","article-title":"AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis","volume":"13","author":"Wilkinson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025051309090612300_bib55","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/1535-7163.MCT-09-0323","article-title":"Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells","volume":"8","author":"Kaestner","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2025051309090612300_bib56","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1073\/pnas.80.18.5573","article-title":"Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine","volume":"80","author":"Dolbeare","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051309090612300_bib57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.devcel.2004.09.002","article-title":"Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint","volume":"7","author":"Rieder","year":"2004","journal-title":"Dev Cell"},{"key":"2025051309090612300_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","article-title":"Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survival","volume":"9","author":"Oser","year":"2019","journal-title":"Cancer Discov"},{"key":"2025051309090612300_bib59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41416-024-02584-z","article-title":"Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells","volume":"130","author":"Shah","year":"2024","journal-title":"Br J Cancer"},{"key":"2025051309090612300_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm2163","article-title":"The spindle-assembly checkpoint in space and time","volume":"8","author":"Musacchio","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025051309090612300_bib61","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1073\/pnas.80.10.2926","article-title":"Monoclonal antibodies to mitotic cells","volume":"80","author":"Davis","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051309090612300_bib62","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1097-2765(02)00540-3","article-title":"The anaphase-promoting complex: proteolysis in mitosis and beyond","volume":"9","author":"Peters","year":"2002","journal-title":"Mol Cell"},{"key":"2025051309090612300_bib63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ceb.2013.06.005","article-title":"4D-networking by mitotic phosphatases","volume":"25","author":"Qian","year":"2013","journal-title":"Curr Opin Cell Biol"},{"key":"2025051309090612300_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov"},{"key":"2025051309090612300_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025051309090612300_bib66","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.molcel.2020.05.012","article-title":"POLE mutation spectra are shaped by the mutant allele identity, its abundance, and mismatch repair status","volume":"78","author":"Hodel","year":"2020","journal-title":"Mol Cell"},{"key":"2025051309090612300_bib67","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"2025051309090612300_bib68","doi-asserted-by":"crossref","first-page":"1026020","DOI":"10.3389\/fonc.2022.1026020","article-title":"Unweaving the mitotic spindle: a focus on Aurora kinase inhibitors in lung cancer","volume":"12","author":"Stefani","year":"2022","journal-title":"Front Oncol"},{"key":"2025051309090612300_bib69","doi-asserted-by":"crossref","first-page":"325ra17","DOI":"10.1126\/scitranslmed.aad2355","article-title":"Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo","volume":"8","author":"Ashton","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0028\/3540625\/crc-24-0028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/4\/719\/3602014\/crc-24-0028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/4\/719\/3602014\/crc-24-0028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T09:09:22Z","timestamp":1747127362000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/4\/719\/762172\/Functional-Profiling-of-p53-and-RB-Cell-Cycle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0028","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29051906","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904165","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051918","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904084","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051978","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904096","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904153","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904141","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904129","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904117","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051921","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051981","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051927","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904102","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904162","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904150","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904126","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904114","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904138","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051942","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904111","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904078","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904135","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904123","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051912","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051948","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051936","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904159","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904147","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051975","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904081","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904093","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051951","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904144","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904132","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904156","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051945","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904120","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904075","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051969","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904087","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904108","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29051972","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28904090","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7795994","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}